Rue des Chasseurs Ardennais 3
4031 LIEGE
Belgium
[email protected] syngulon.com

Syngulon leverages bacteriocins, discovered by André Gratia, to develop innovative genetic technologies. These ribosomally-produced antimicrobials offer a novel solution to combat drug resistance.

About

Related news

News

Learn more

Syngulon and ULB announce the issuance by the USPTO of a first joint patent covering an antibiotic-free selection technology

    Press release

28.05.2024